A systematic review of cost-effectiveness analyses of
continuous versus intermittent renal replacement therapy in
acute kidney injury

J 2022

A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury

SINGH, A., Mohammad Salman HUSSAIN, V. KHER, A. J. PALMER, M. JOSE et. al.

Basic information

Original name

A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury

Authors

SINGH, A., Mohammad Salman HUSSAIN (356 India, belonging to the institution), V. KHER, A. J. PALMER, M. JOSE and B. ANTONY (guarantor)

Edition

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, ABINGDON, TAYLOR & FRANCIS LTD, 2022, 1473-7167

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.300

RIV identification code

RIV/00216224:14110/22:00124962

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1080/14737167.2021.1916471

UT WoS

000646164100001

Keywords in English

Acute kidney injury; cost-effectiveness analysis; CRRT; dialysis; health economics; IRRT; systematic review

Abstract

V originále

Introduction Though cost-effectiveness analyses (CEAs) have evaluated continuous renal replacement therapy (RRTs) and intermittent RRTs in acute kidney injury (AKI) patients; it is yet to establish which RRT technique is most cost-effective. We systematically reviewed the current evidence from CEAs of CRRT versus IRRT in patients with AKI. Areas covered PubMed, EMBASE, and Cochrane databases searched for CEAs comparing two RRTs. Overall, seven CEAs, two from Brazil and one from US, Canada, Colombia, Belgium, and Argentina were included. Five CEAs used Markov model, three reported following CHEERS, none accounted indirect costs. Time horizon varied from 1-year-lifetime. Marginal QALY gain with CRRT compared to IRRT was reported across CEAs. Older CEAs found CRRT to be costlier and not cost-effective than IRRT (ICER 2019 US$: 152,671$/QALY); latest CEAs (industry-sponsored) reported CRRT to be cost-saving versus IRRT (-117,614$/QALY). Risk of mortality, dialysis dependence, and incidence of renal recovery were the key drivers of cost-effectiveness. Expert opinion CEAs of RRTs for AKI show conflicting findings with secular trends. Latest CEAs suggested CRRT to be cost-effective versus IRRT with dialysis dependence rate as major driver of cost-effectiveness. Future CEAs, preferably non-industry sponsored, may account for indirect costs to improve the generalizability of CEAs.

Citovat

SINGH, A., Mohammad Salman HUSSAIN, V. KHER, A. J. PALMER, M. JOSE and B. ANTONY. A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. ABINGDON: TAYLOR & FRANCIS LTD, 2022, vol. 22, No 1, p. 27-35. ISSN 1473-7167. Available from: https://dx.doi.org/10.1080/14737167.2021.1916471.

@article{1785581,
   author = {Singh, A. and Hussain, Mohammad Salman and Kher, V. and Palmer, A. J. and Jose, M. and Antony, B.},
   article_location = {ABINGDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1080/14737167.2021.1916471},
   keywords = {Acute kidney injury; cost-effectiveness analysis; CRRT; dialysis; health economics; IRRT; systematic review},
   language = {eng},
   issn = {1473-7167},
   journal = {EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH},
   title = {A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury},
   url = {https://www.tandfonline.com/doi/full/10.1080/14737167.2021.1916471},
   volume = {22},
   year = {2022}
}

TY  - JOUR
ID  - 1785581
AU  - Singh, A. - Hussain, Mohammad Salman - Kher, V. - Palmer, A. J. - Jose, M. - Antony, B.
PY  - 2022
TI  - A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury
JF  - EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
VL  - 22
IS  - 1
SP  - 27-35
EP  - 27-35
PB  - TAYLOR & FRANCIS LTD
SN  - 14737167
KW  - Acute kidney injury
KW  - cost-effectiveness analysis
KW  - CRRT
KW  - dialysis
KW  - health economics
KW  - IRRT
KW  - systematic review
UR  - https://www.tandfonline.com/doi/full/10.1080/14737167.2021.1916471
N2  - Introduction Though cost-effectiveness analyses (CEAs) have evaluated continuous renal replacement therapy (RRTs) and intermittent RRTs in acute kidney injury (AKI) patients; it is yet to establish which RRT technique is most cost-effective. We systematically reviewed the current evidence from CEAs of CRRT versus IRRT in patients with AKI. Areas covered PubMed, EMBASE, and Cochrane databases searched for CEAs comparing two RRTs. Overall, seven CEAs, two from Brazil and one from US, Canada, Colombia, Belgium, and Argentina were included. Five CEAs used Markov model, three reported following CHEERS, none accounted indirect costs. Time horizon varied from 1-year-lifetime. Marginal QALY gain with CRRT compared to IRRT was reported across CEAs. Older CEAs found CRRT to be costlier and not cost-effective than IRRT (ICER 2019 US$: 152,671$/QALY); latest CEAs (industry-sponsored) reported CRRT to be cost-saving versus IRRT (-117,614$/QALY). Risk of mortality, dialysis dependence, and incidence of renal recovery were the key drivers of cost-effectiveness. Expert opinion CEAs of RRTs for AKI show conflicting findings with secular trends. Latest CEAs suggested CRRT to be cost-effective versus IRRT with dialysis dependence rate as major driver of cost-effectiveness. Future CEAs, preferably non-industry sponsored, may account for indirect costs to improve the generalizability of CEAs.
ER  -

SINGH, A., Mohammad Salman HUSSAIN, V. KHER, A. J. PALMER, M. JOSE and B. ANTONY. A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury. \textit{EXPERT REVIEW OF PHARMACOECONOMICS \&{} OUTCOMES RESEARCH}. ABINGDON: TAYLOR \&{} FRANCIS LTD, 2022, vol.~22, No~1, p.~27-35. ISSN~1473-7167. Available from: https://dx.doi.org/10.1080/14737167.2021.1916471.

Detailed Information on Publication Record